Alunbrig (brigatinib) — United Healthcare
non-small cell lung cancer (NSCLC)
Initial criteria
- Diagnosis of non-small cell lung cancer (NSCLC)
- Disease is metastatic OR recurrent OR advanced
- Tumor is anaplastic lymphoma kinase (ALK)-positive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Alunbrig therapy
Approval duration
12 months